NEW YORK (GenomeWeb) – Vermillion said today that CareFirst Blue Cross/Blue Shield has begun covering the company's OVA1 ovarian cancer test.

According to Vermillion, CareFirst is the largest insurer in Maryland, covering 3.4 million people, representing more than 40 percent of the state's population.

With the announcement, Vermillion now has commercial coverage for OVA1 for more than 16 million lives. The company received another positive coverage decision for the test in April from Blue Cross/Blue Shield of Michigan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.